U S FDA approves Bristol Myers bowel disease treatment reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Dive Brief:
GlaxoSmithKline will stop enrolling cancer patients into two mid-stage studies testing a closely watched cancer immunotherapy alongside Merck & Co. s Keytruda, marking another setback for the British drugmaker s ambitions in oncology research.
The decision followed a recommendation from an independent monitoring committee that oversees one of the trials. In a Wednesday statement, GSK said it will evaluate the totality of the data to determine the impact on its broader development plans for the drug, called feladilimab.
Feladilimab is a top drug prospect for GSK, one of a class of experimental cancer medicines known as ICOS receptor agonists. But their potential may now be in question after GSK s decision and the failure of a study testing a similar drug from Jounce Therapeutics last fall.